scholarly journals Frontal hypometabolism in elderly breast cancer survivors determined by [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET): a pilot study

2014 ◽  
Vol 30 (6) ◽  
pp. 587-594 ◽  
Author(s):  
Laura L. Boles Ponto ◽  
Yusuf Menda ◽  
Vincent A. Magnotta ◽  
Torricia H. Yamada ◽  
Natalie L. Denburg ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Positron Emission Tomography ◽  
Pilot Study ◽  
Cancer Survivors ◽  
Breast Cancer Survivors ◽  
Emission Tomography ◽  
18F Fluorodeoxyglucose ◽  
Positron Emission

POSITRON EMISSION TOMOGRAPHY (PET) OF BREAST CANCER USING 18F-FLUORODEOXYGLUCOSE (FDG)

1992 ◽  
Vol 17 (3) ◽  
pp. 253
Author(s):  
E. E. Kim ◽  
B. T. Kim ◽  
T. P. Haynie ◽  
D. A. Podoloff ◽  
W. H. Wong ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Positron Emission Tomography ◽  
Emission Tomography ◽  
18F Fluorodeoxyglucose ◽  
Positron Emission

scholarly journals Genomic Signature of the Standardized Uptake Value in 18F-Fluorodeoxyglucose Positron Emission Tomography in Breast Cancer

Cancers ◽  
2020 ◽  
Vol 12 (2) ◽  
pp. 497
Author(s):  
Seon-Kyu Kim ◽  
Sung Gwe Ahn ◽  
Jeong-Yeon Mun ◽  
Mi-So Jeong ◽  
Soong June Bae ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Positron Emission Tomography ◽  
Fdg Pet ◽  
Standardized Uptake Value ◽  
Emission Tomography ◽  
Diagnostic Tools ◽  
Fluorodeoxyglucose Positron Emission Tomography ◽  
18F Fluorodeoxyglucose ◽  
Positron Emission ◽  
Fluorodeoxyglucose Positron Emission

The standardized uptake value (SUV), an indicator of the degree of glucose uptake in 18F-fluorodeoxyglucose positron emission tomography (FDG-PET), has been used for predicting the clinical behavior of malignant tumors. However, its characteristics have been insufficiently explored at the genomics level. Here, we aim to identify genomic signatures reflecting prognostic SUV characteristics in breast cancer (BRC). Through integrative genomic profiling of 3710 BRC patients, including 254 patients who underwent preoperative FDG-PET, we identified an SUV signature, which showed independent clinical utility for predicting BRC prognosis (hazard ratio [HR] 1.27, 95% confidence interval [CI] = 1.12 to 1.45, p = 2.23 × 10−4). The risk subgroups classified by the signature exhibited mutually exclusive mutation patterns of TP53 and PIK3CA and showed significantly different responsiveness to immunotherapy. Experimental assays revealed that a signaling axis defined by TP53–FOXM1 and its downstream effectors in glycolysis–gluconeogenesis, including LDHA, might be important mediators in the FDG-PET process. Our molecular characterizations support an understanding of glucose metabolism and poor prognosis in BRC with a high SUV, utilizable in clinical practice to assist other diagnostic tools.

Sign in / Sign up

Export Citation Format

Share Document